VC-backed Corium files for IPO

Corium International has filed for an IPO. The number of shares that will be sold as well as the price range of the offering have yet to be set. Corium will trade its stock on the NASDAQ under the ticker symbol “CORI.” Jefferies and Leerink Partners will serve as lead underwriters. Based in Menlo Park, Calif., Corium is a developer of advanced transdermal drug delivery technologies and products. It is backed by Essex Woodlands Health Ventures, Quantum Technology Partners and Aphelion Capital.

PRESS RELEASE

MENLO PARK, Calif., March 3, 2014 /PRNewswire/ — Corium International, Inc., a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal pharmaceutical products, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of its common stock. All of the shares to be sold in the proposed offering will be offered by Corium. The number of shares to be sold and the price range for the proposed offering have not yet been determined. Corium plans to list its common stock on the NASDAQ Global Market under the ticker symbol “CORI.”
Jefferies LLC and Leerink Partners LLC will act as joint book-running managers for the offering. Needham & Company, LLC and FBR Capital Markets & Co. will act as co-managers.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. A copy of the preliminary prospectus may be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by telephone at (877) 547-6340, or by email at prospectus_department@jefferies.com; or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, or by email at syndicate@leerink.com.

Related Posts

Leave a Reply

PEHUB Community

Join the 12502 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget